Department of Surgery, College of Medicine, University of Arizona, Tucson, Arizona 85724, USA.
Curr Opin Organ Transplant. 2010 Feb;15(1):124-30. doi: 10.1097/MOT.0b013e32833553f8.
The aim of this article is to review recent reports on whole pancreas and islet cell transplantation. It focuses on 'what the call to the future looks like' for both therapies as treatment options for those type 1 diabetes patients who do not respond well to conventional therapy.
The major benefit of pancreas transplantation is the reversal of diabetes improvement of diabetes complications. Although the procedure requires major surgery and life-long immunosuppression, it remains the gold standard for a specific population of patients who suffer from type 1 diabetes and who do not respond to conventional therapy. Allogeneic islet transplantation is a promising alternative to pancreas transplantation, but patient outcomes remain less than optimal and significant progress is required in order for this procedure to be considered a reliable therapy.
Several factors have to be taken into consideration before making the decision of which of these procedures would better suit a patient with type 1 diabetes.
本文旨在综述全胰腺和胰岛细胞移植的最新报道。重点介绍了这两种治疗方法作为那些对常规治疗反应不佳的 1 型糖尿病患者的治疗选择，“未来的前景如何”。
胰腺移植的主要益处是逆转糖尿病，改善糖尿病并发症。尽管该手术需要大手术和终身免疫抑制，但它仍然是对那些患有 1 型糖尿病且对常规治疗无反应的特定患者群体的金标准。同种异体胰岛移植是胰腺移植的一种有前途的替代方法，但患者的结果仍不理想，需要取得重大进展，才能将该手术视为一种可靠的治疗方法。
在决定哪种手术更适合 1 型糖尿病患者之前，需要考虑几个因素。
